title: Combined endocrine blockade in premenopausal breast cancer: a superior therapeutic option for adjuvant management?
authors.forename: Manish
authors.initials: M
authors.lastname: Kohli
authors.forename: Mir Ali
authors.initials: MA
authors.lastname: Khan
authors.forename: Paulette
authors.initials: P
authors.lastname: Mehta
authors.forename: Laura
authors.initials: L
authors.lastname: Hutchins
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D017273:Goserelin / Q000008:administration & dosage*; D006801:Humans; D008727:Methotrexate / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local; D010052:Ovariectomy; D017697:Premenopause; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen; D017273:Goserelin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate